Free Trial

Schrodinger (SDGR) Competitors

Schrodinger logo
$18.57 -0.21 (-1.12%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$18.71 +0.14 (+0.75%)
As of 09/12/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SDGR vs. NUVL, MRUS, CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, and PCVX

Should you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Schrodinger vs. Its Competitors

Nuvalent (NASDAQ:NUVL) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Nuvalent had 2 more articles in the media than Schrodinger. MarketBeat recorded 12 mentions for Nuvalent and 10 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.09 beat Nuvalent's score of 0.95 indicating that Schrodinger is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvalent
7 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Schrodinger
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 21.0% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Schrodinger has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvalentN/AN/A-$260.76M-$4.90-16.42
Schrodinger$207.54M6.59-$187.12M-$2.48-7.49

Nuvalent has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.

Nuvalent presently has a consensus price target of $120.91, indicating a potential upside of 50.25%. Schrodinger has a consensus price target of $27.83, indicating a potential upside of 49.88%. Given Nuvalent's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvalent is more favorable than Schrodinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvalent
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
3.08
Schrodinger
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Nuvalent has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Nuvalent's return on equity of -32.58% beat Schrodinger's return on equity.

Company Net Margins Return on Equity Return on Assets
NuvalentN/A -32.58% -30.14%
Schrodinger -76.22%-45.70%-24.81%

Summary

Nuvalent and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

Get Schrodinger News Delivered to You Automatically

Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SDGR vs. The Competition

MetricSchrodingerMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.37B$2.16B$5.78B$10.18B
Dividend YieldN/AN/A5.73%4.60%
P/E Ratio-7.4938.0975.4626.02
Price / Sales6.5910.28464.4091.13
Price / CashN/A58.5825.8129.91
Price / Book3.2111.6812.166.25
Net Income-$187.12M-$63.67M$3.29B$270.76M
7 Day Performance-4.48%-2.05%0.73%2.54%
1 Month Performance-4.18%2.88%4.41%5.73%
1 Year Performance-10.42%133.43%62.61%25.85%

Schrodinger Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SDGR
Schrodinger
3.524 of 5 stars
$18.57
-1.1%
$27.83
+49.9%
-10.4%$1.37B$207.54M-7.49790Positive News
NUVL
Nuvalent
2.9934 of 5 stars
$76.58
+0.7%
$120.80
+57.7%
-8.0%$5.52BN/A-15.6340Insider Trade
MRUS
Merus
2.878 of 5 stars
$65.84
-0.4%
$88.75
+34.8%
+38.8%$4.98B$36.13M-11.9737Positive News
CRSP
CRISPR Therapeutics
3.2794 of 5 stars
$51.83
-2.3%
$71.60
+38.1%
+15.0%$4.71B$37.31M-9.55460Positive News
TGTX
TG Therapeutics
4.2988 of 5 stars
$29.33
+1.3%
$46.25
+57.7%
+35.5%$4.65B$329M79.27290Positive News
Insider Trade
ACAD
ACADIA Pharmaceuticals
4.376 of 5 stars
$25.99
-0.9%
$28.88
+11.1%
+44.7%$4.38B$957.80M19.54510
KRYS
Krystal Biotech
4.9657 of 5 stars
$147.70
-2.0%
$210.38
+42.4%
-28.7%$4.27B$290.52M30.02210Positive News
CYTK
Cytokinetics
4.3865 of 5 stars
$35.33
-5.4%
$71.58
+102.6%
-8.5%$4.23B$85.74M-6.93250Positive News
MENS
Jyong Biotech
N/A$54.81
-1.3%
N/AN/A$4.17BN/A0.0031News Coverage
Gap Down
ADMA
ADMA Biologics
3.6904 of 5 stars
$17.26
-0.7%
$27.67
+60.3%
-10.9%$4.12B$426.45M20.07530Positive News
PCVX
Vaxcyte
2.3331 of 5 stars
$30.79
+0.1%
$136.50
+343.3%
-72.3%$4.00BN/A-7.49160Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SDGR) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners